This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Welcome👋to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) September 28, 2023
"We seek it here,we seek it there.."
Aye,we nephrologists seek it everywhere.
Couple of weeks ago, NephJC discussed the intriguing urinary biomarker study for diagnosis of AIN by @dmoledina et al.
✳️#NephJC catch-up✳️of the damned, elusive chase!👇 pic.twitter.com/OsiMjOaKEA
Basic science week - catch up in only Ten Tweets here.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) October 26, 2022
✳️10 tweets #NephJC catch-up ✳️
Perplexed by how gene dosage plays a role in ADPKD? Fascinated by futuristic stories of miRNA,CRISPR & want to see an application closer to daily life?
Read on!Here’s some good news for the ADPKD patient in your clinic. pic.twitter.com/44iFttuRJK
